Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Gross Profit: 2013-2024

Historic Gross Profit for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to $16.2 million.

  • Zevra Therapeutics' Gross Profit rose 1679.67% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.1 million, marking a year-over-year increase of 295.48%. This contributed to the annual value of $16.2 million for FY2024, which is 35.96% down from last year.
  • According to the latest figures from FY2024, Zevra Therapeutics' Gross Profit is $16.2 million, which was down 35.96% from $25.3 million recorded in FY2023.
  • Zevra Therapeutics' Gross Profit's 5-year high stood at $26.6 million during FY2021, with a 5-year trough of $9.9 million in FY2022.
  • Moreover, its 3-year median value for Gross Profit was $16.2 million (2024), whereas its average is $17.1 million.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 62.62% in 2022, then spiked by 154.43% in 2023.
  • Over the past 5 years, Zevra Therapeutics' Gross Profit (Yearly) stood at $13.3 million in 2020, then soared by 100.11% to $26.6 million in 2021, then slumped by 62.62% to $9.9 million in 2022, then surged by 154.43% to $25.3 million in 2023, then plummeted by 35.96% to $16.2 million in 2024.